[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ihab Elsayed Hassan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100619811",false,"NCT07349472","Pentoxifylline in Patients With Ulcerative Colitis","Clinical Study Evaluating Safety and Efficacy of Pentoxifylline in Patients With Ulcerative Colitis","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Both male and female will be included\n* Negative pregnancy test and effective contraception.\n* Mild and moderate UC patients\n\nExclusion Criteria:\n\n* Breast feeding\n* Significant liver and kidney function abnormalities\n* Diabetic patients\n* Colorectal cancer patients\n* Patients with severe UC\n* Patients taking rectal or systemic steroids\n* Patients taking immunosuppressives or biological therapies\n* Addiction to alcohol and \u002F or drugs\n* Known allergy to the studied medications","ALL","18 Years","70 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.",[26],"Inflammatory Bowel Diseases","RECRUITING","2026-04-11",{"date":30,"type":31},"2026-04-15","ACTUAL",{"date":33,"type":31},"2026-01-20",{"date":35,"type":20},"2027-02-20",{"name":37,"class":38},"Ihab Elsayed Hassan","OTHER",1,{"id":41,"slug":4,"hasResults":10,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":10,"sex":15,"minAge":46,"maxAge":17,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":39},"100621431","NCT07370532","Etoricoxib in Patients With Parkinsonian Disease","Clinical Study to Evaluate Safety and Efficacy of Etoricoxib in Patients With Parkinson's Disease Treated With Conventional Treatment","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Both male and female will be included.\n* Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.\n\nExclusion Criteria:\n\n* Breast feeding\n* Patients with significant liver and kidney function abnormalities.\n* Alcohol and \u002F or drug abusers.\n* Patients with known allergy to the study medications\n* Pregnant women and women with planned pregnancy.\n* Patients who are currently using other anti-inflammatory drugs.","50 Years",{"count":19,"type":20},[23],"Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).",[51],"Parkinson Disease","2026-04-02",{"date":54,"type":31},"2026-04-08",{"date":56,"type":31},"2026-01-30",{"date":58,"type":20},"2027-11-20",{"name":37,"class":38},""]